Liquidia is a biopharmaceutical company focused on the development, manufacturing and commercialization of products with focus directed towards the treatment of pulmonary hypertension (PH). Co. conducts research and manufacturing of products by applying its proprietary PRINT® technology, a particle engineering platform. Co.'s products and candidates for PH include: YUTREPIATM (treprostinil) Inhalation Powder to Treat PAH, which is an inhaled dry powder formulation of treprostinil; and Treprostinil Injection, a Generic Version of Remodulin®, which contains the same active ingredient, same strength, same dosage forms and same inactive ingredient amounts as Remodulin®. We show 22 historical shares outstanding datapoints in our LQDA shares outstanding history coverage, used to compute LQDA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing LQDA market cap history over the course of time is important for investors
interested in comparing LQDA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of LQDA versus a peer is one thing; comparing
LQDA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like LQDA can fluctuate over the course of history.
With this page we aim to empower investors researching LQDA by allowing them to research the LQDA market cap history. |
Free LQDA Email Alerts:
Video: The Importance of Market Cap
